Expediting drug development--the FDA's new 'breakthrough therapy' designation

The FDA's new “breakthrough therapy” designation for investigational drugs adds to the agency's portfolio of expedited programs for serious conditions. The designation requires preliminary clinical evidence demonstrating substantial improvement over existing therapies.